Company · Private
Retro Biosciences
Focused company targeting ten additional years of healthy human lifespan through reprogramming, plasma-inspired interventions and autophagy restoration.
EvidenceEarlyAwaiting Phase 1 readout
Listing
Private
Ticker
—
Headquarters
Redwood City, US
Founded
2021
Technology
Cellular reprogramming, autophagy
Category
Market cap
Private
Longevity thesis
Small, aggressive teams working on a narrow set of aging mechanisms can reach the clinic faster than broad platform organisations.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| RTR-242 | Phase 1 | Autophagy restoration in neurodegeneration |
| Reprogramming toolkit | Preclinical | Cell rejuvenation |
Recent developments
- 2 Aug 2026Dosed additional Phase 1 cohort for its autophagy programme.
Scientific evidence
EvidenceEarly
First-in-human safety data only; no efficacy readout yet.
LONGEFI analysis
The first credible clinical translation of reprogramming-adjacent biology. A clean safety package would be a meaningful field-level signal well beyond this company.
Analysis is research commentary. It is not investment advice or a recommendation.